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Abstract: Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths 
worldwide. As with other cancers, CRC is a genetic disease, however, several risk factors 
including diet and chronic colitis predispose to the disease. Mutations in the tumor suppressor 
adenomatous polyposis coli (APC) initiate most cases of CRC. Recent data from mouse models 
suggest that APC mutations and colitis are not completely independent factors in colorectal 
carcinogenesis. Here, we review the evidence supporting an interaction between APC muta-
tions and chronic colitis. We will also discuss possible pathophysiologic mechanisms behind 
this interaction.
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Introduction
Colorectal cancer (CRC) is the fourth largest cancer killer worldwide and accounts 
for about 9% of cancer related deaths in the Unites States.1 CRC is a genetic dis-
ease that results from accumulation of mutations in tumor suppressor genes and 
proto-oncogenes.2 There are many factors that increase CRC risk, including age, diet, 
ethnic background, known genetic alterations, family history of the disease, and chronic 
colon inflammation (colitis).3 Mouse and rat models developed to study CRC have 
confirmed some of the risk factors elucidated from human cases. These models also 
revealed many of the molecular events underlying different risk factors and interactions 
between various risk factors.4,5 In this review we will discuss the interaction between 
the most common genetic alteration in CRC, mutations in the tumor suppressor APC, 
and a major predisposing factor for CRC, chronic colitis, as illuminated by studies 
of rodent models.
APC structure, functions, Wnt signaling
Mutations in APC are the most prevalent among genetic alterations found in CRC.6 
These APC mutations occur early during CRC tumorigenesis and are considered the 
initiating events of CRC.2 In addition to the frequent somatic APC mutations, a more 
rare inheritance of a germline APC mutation in familial adenomatous polyposis (FAP) 
patients leads to development of tens to thousands of colonic adenomatous polyps.7,8 
Although benign, these polyps have, on average, a 1%–5% chance of undergoing 
malignant transformation. Considering the number of polyps that typically develop in 
FAP patients, CRC is nearly inevitable, unless the colon is surgically resected.9





The APC gene encodes a large multidomain protein, 
2,843 amino acids, that interacts with many other proteins 
and is implicated in multiple cellular processes.10,11 The 
most characterized function of APC is to antagonize Wnt 
signaling-induced cellular proliferation by destroying the 
oncoprotein β-catenin.12 APC is a component of a multipro-
tein cytoplasmic complex that phosphorylates and targets 
β-catenin for proteasome-mediated degradation. In the 
presence of Wnt ligand, or in the absence of functional APC, 
β-catenin accumulates in the cytoplasm and translocates to 
the nucleus, where it binds to the transcriptional cofactor 
TCF/LEF to alter the expression of Wnt target genes.13 Most 
β-catenin-responsive genes are induced eg, MYC, CyclinD1, 
and AXIN2; and a minority are downregulated, eg, HATH114–17 
(for an updated list of Wnt target genes see the Wnt homep-
age http://www.stanford.edu/group/nusselab/cgi-bin/wnt/
target_genes).
Wnt signaling plays an important role in maintaining the 
intestinal epithelial architecture.18 The intestine is lined by a 
single layer of columnar epithelial cells that are arranged in 
finger-like projections into the lumen (villi, only in the small 
intestine) and sac-like invaginations (crypts, in both the small 
and large intestines). Stromal cells at the crypt base secrete 
Wnt ligands that maintain a gradient Wnt concentration 
along the length of the crypt. Intestinal stem cells located 
at the crypt base (highest concentration of Wnt) divide to 
maintain the stem cell population and also produce progenitor 
transit amplifying cells (TA).19 TA cells further divide until 
they reach the upper one-third of the crypt (with lower Wnt 
concentration) where they start to differentiate into various 
adult cell types.13,20 The inability of mutant APC to antagonize 
Wnt signaling results in continuing proliferation, lack of dif-
ferentiation, and intestinal tumor formation.21–23
Wnt-independent roles of APC include regulation of 
cellular adhesion, migration, cytoskeletal organization, 
spindle formation, cellular differentiation, and chromo-
some segregation.10,24 APC coimmunoprecipitates with the 
adherens junction protein, β-catenin.25,26 Full-length, but not 
truncated, APC colocalizes with microtubules and also con-
centrates near the leading edge of migrating epithelial cells.27 
This microtubule interaction involves the C-terminal part of 
APC and is unrelated to Wnt antagonism.28 APC interacts 
with the microtubule-associated protein EB129,30 and with 
the intermediate filament proteins Lamin B1 and Keratin 81 
in cultured cells.31 Mutations in APC have been associated 
with chromosomal instability in both colon cancer cell lines 
and mouse embryonic stem cells.24,32 Moreover, in mouse 
intestinal epithelial cells, Apc mutations affect the sensitivity 
of cultured cells to microtubule poisons, inhibiting spindle 
assembly checkpoint-induced mitotic arrest in response to 
low doses of microtubule poisons.33
In addition to the cytoplasmic functions described above, 
APC moves between the cytoplasm and the nucleus.34–36 This 
nucleo–cytoplasmic shuttling is aided by two nuclear local-
ization signals (NLS) in the C-terminal half of APC and five 
nuclear export signals.36,37 Nuclear APC can antagonize Wnt 
signaling by sequestering nuclear β-catenin from interaction 
with the TCF/LEF transcription factor.35,38
Other proposed functions for nuclear APC include DNA 
synthesis, cell cycle regulation, and DNA repair.36 APC inter-
acts with Topoisomerase IIα, an enzyme essential in DNA 
replication and cell cycle progression.39,40 APC also interacts 
with PCNA, FEN-1, and polymerase-β, components of long 
patch-base excision repair (LP-BER),41–45 and affects CREB-
C/EBP- mediated transcription.46 Although the significance is 
not completely understood, APC appears to directly interact 
with A/T-rich DNA sequences.47 It is important to note that 
cancer-associated mutations in APC usually result in deletion 
of the C-terminus of the protein, including several protein 
interaction domains and both NLS.48
Modeling Apc in rodents
To study APC biological functions in development and can-
cer, several mouse and rat models have been made. A more 
comprehensive review of these models are provided in other 
articles.4,5 Most of these models have mutations resulting in 
truncated Apc, with lengths ranging from complete deletion 
to deletion of only the C-terminal 300 amino acids. Figure 
1 shows protein products resulting from Apc mutations in 
rodent models that will be discussed in this review. These 
models displayed some of the same phenotypes as patients 
with germ line mutations of APC.5 Mice with Apc truncation 
involving at least the C-terminal half of Apc develop intesti-
nal tumors, though the number of tumors does not correlate 
with the extent of truncation.4 As in FAP patients, Apc trun-
cating mutations in these models are lethal in a homozygous 
state, and tumor development requires mutation or loss of the 
other (wild type) Apc allele.5 Tumors from these mouse mod-
els resemble those found in patients at both the histological 
and molecular levels.49 However, the mouse tumors mainly 
develop in small intestine, whereas FAP patients harbor 
mostly colonic tumors.4 Rats with a mutation that truncates 
Apc at amino acid 1137 develop tumors in both the small and 
large intestine.50 In addition, unlike in humans, progression 
to carcinoma is not typically seen in most Apc mutant mice, 
presumably because of their limited lifespan.51 There are also 























Figure 1 Apc mutant rodent models.
Notes: The 2,843 amino acid-long Apc protein with binding domains marked as follows: APC, homodimerization; Crm1/exportin 1 binds NeS to mediate nuclear export; 
PCNA (orange line), processivity factor for DNA polymerase δ; eb1, binds and regulates MT plus ends. Shown below the schematic are the Apc proteins from rodent models 
referenced in this review.
Abbreviations: PCNA, proliferating cell nuclear antigen; MT, microtubule; eb1, end binding 1; Dlg, discs large; NLS, nuclear localization signals.
some differences in the extraintestinal phenotypes in rodent 
Apc models and human FAP cases.4,5 Recently, several new 
Apc rodent models have been generated to facilitate testing 
the function of a specific region or subcellular localization of 
Apc. These include a rat model with a shorter truncation (Apc 
KAD rat),52 and mouse models with interstitial mutations 
deleting a specific Apc domain (Apc∆SAMP)53 or disrupting 
Apc nuclear localization signals (ApcmNLS).54
In addition to rodent models with germ line Apc muta-
tions, several models use LoxP-Cre technology to delete 
all, or portions, of Apc in a conditional manner.5 In this 
system, deletion of a genomic region flanked by two LoxP1 
sites is induced by expression of Cre recombinase enzyme. 
Cre-mediated deletion is specified by placing Cre under the 
control of a tissue-specific, developmental stage-specific, 
or drug-inducible promoter, or by infecting the tissue with 
adenovirus that expresses Cre recombinase.5 CPC–APC, 
Apc580D, and Apc∆468 are three such models discussed further 
in this review (Figure 1).
Chronic colitis
Besides APC mutations, other factors such as chronic 
inflammation increase risk of CRC.55 Inflammation is an 
immunological reaction to protect from harmful agents, 
including invading microorganisms.56,57 An estimated 15% 
of all cancers are associated with chronic inflammation.58 
For the colon, patients with an inflammatory bowel disease 
(IBD, ulcerative colitis, or Crohn’s disease) have 2–4 times 
increased risk of CRC compared to the general population.55 
This colitis-associated CRC is more aggressive and has a 
relatively poor prognosis.59 Many inflammatory mediators 
have roles in the protumorigenic effects of IBD-associated 
inflammation.55,59 These mediators are secreted by inflamma-
tory as well as epithelial cells, and affect cellular survival, 
proliferation, apoptosis, and differentiation.55,59
Modeling chronic colitis in rodents
To facilitate studying colitis, a dextran sodium sulfate (DSS) 
model was developed in the rat and adapted to both hamster 
and mouse.60–63 In this model, colonic inflammation is usually 
induced by administration of DSS (1%–4%) in drinking water 
for 3–7 days. Mice are then typically given untreated water 
for 2–4 weeks, with the cycle repeated up to four times.61
The DSS model appears similar to human ulcerative 
colitis at both the pathological and molecular levels.64 The 
pathological changes seen during the first DSS cycle in 
murine colons include loss of crypt structure and ulceration, 
symptoms that are also seen in the acute phase of the human 
disease.65 Following the first cycle, mucosal regeneration, 
crypt branching and shortening, glandular disorder, and 
diarrhea are also seen; these also occur in the chronic phase 
of ulcerative colitis in humans. As with human IBD, mice 
treated with DSS also show an increased incidence of colonic 
tumors that varies somewhat based on the protocol of DSS 
treatment.65,66 For Swiss mice treated with four cycles (7 days 
each) of 4% DSS, the colon tumor incidence is about 37.5% 
at 120 days and more than half of the lesions that develop 
in DSS-treated mice are flat, similar to those seen in the 
human disease.66 Some tumors in this model show malig-
nant transformation.66 Molecular changes in tumors from 
DSS-treated mice also recapitulate those in human colitis-
associated colorectal carcinogenesis.66,67
Administration of a mutagen increases the incidence 
of colonic tumors in the murine DSS model.64 The most 





commonly used mutagen is azoxymethane (AOM), which 
induces O6-methylguanine DNA adducts resulting in GA 
transitions.64 A single intraperitoneal dose of AOM increases 
the incidence of colonic cancer in DSS-treated mice to 
100%.64 Another advantage of including a mutagen in the 
protocol is that it allows reduction of the DSS dose in mice, 
and decreases the mortality from DSS-associated acute 
colitis. Again, different groups use different regimens of 
AOM treatment: single or multiple doses of 7.5–20 mg/kg. 
A single AOM dose of 10 mg/kg alone without DSS treatment 
is not sufficient to induce tumors in wild-type mice.64
β-catenin mutations in exon 3 are detected in most 
tumors from AOM–DSS-treated mice.68 These mutations 
are expected to prevent phosphorylation and targeting of 
β-catenin for destruction, resulting in cellular accumulation 
and nuclear translocation of β-catenin, and promiscuous 
activation of Wnt signaling.68 On the other hand, many AOM-
induced tumors in rats have Apc mutations.69 Both mice and 
rats treated with AOM–DSS have activating mutations of the 
proto-oncogene, Kras, in later stage tumors.68 Wnt and RAS 
pathways are typically activated in human CRC.2
Intestinal epithelial barrier and gut 
microbiome
Colon epithelial cells are exposed to a unique external 
environment. The colon lumen contains hard fecal matter, 
posing a potential threat of mechanical injury.70 In addition, 
the colon is inhabited by over one hundred trillion bacterial 
cells (almost ten times the number of cells in an adult human). 
These gut microbes consume organic materials and secrete 
various secondary metabolites.71,72 Intestinal epithelial cells 
have several lines of defense that prevent bacterial invasion 
or diffusion of harmful substances into the body while allow-
ing absorption of nutrients and beneficial substances.73 These 
combined structural and physiological defenses are termed 
the “intestinal epithelial barrier”.70,74
There are at least seven contributors to the intestinal epi-
thelial barrier (Figure 2). First is the actual physical barrier 
created by mucus, which is continuously secreted by goblet 
cells.75 This mucus is formed of two layers; an outer loose 
layer and an inner adherent layer. The outer mucus lubricates 
the solid contents of the colon to prevent mechanical injury 
and also washes off microorganisms to prevent colonization. 
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Figure 2 intestinal epithelial barrier.
Notes: Protecting the body from invasion by intestinal microbes requires many layers of defense. This illustration depicts the small intestine. The colon would have similar 
components but lack Paneth cells and the villus structure. Goblet cells (green); tight junctions (red); enteroendocrine cells (orange); Paneth cells (yellow).
Abbreviations: DC, dendritic cell; T, T-cell; B, B-cell; TLR, Toll-like receptors; NLR, Nod-like receptors; PAMP, pathogen-associated molecular patterns.
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The inner mucus layer prevents contact of microorganisms 
and their products with the underlying epithelial cells.75 
 Second, epithelial cells lining the colon form a continuous 
sheet with tight junctions that further prevent flora and harm-
ful molecules from penetration.76 Third, the continuous turn-
over of intestinal epithelial cells ensures rapid healing after 
any damage or ulceration.70,77 Fourth, specialized epithelial 
cells, enteroendocrine cells, respond to bacterial invasion 
or toxic substances by secreting active amines to increase 
intestinal movement and fluid secretion, thereby washing off 
potential invaders.78 Fifth, in the small intestine, other special-
ized epithelial cells called Paneth cells secrete antibacterial 
substances. Sixth, intestinal tissue also contains aggregations 
of immune cells (gut-associated lymphoid tissues [GALT] 
and other immune cells) that can detect foreign antigens and 
defend the body against them. M-cells also contribute by 
engulfing antigens and bacteria from the lumen and trans-
porting them to antigen presenting cells for immunological 
processing.70 Seventh, intestinal epithelial cells themselves 
detect different microbes and react to them by expressing 
receptors that can recognize pathogen-associated molecular 
patterns (PAMP) including Toll-like receptors (TLR) and 
Nod-like receptors (NLR). These receptors do not recognize 
specific antigens but specific molecular signatures associated 
with pathogens eg, methylated DNA and peptidoglycans.79
Colitis and APC mutations
CRC is fundamentally a genetic disease, the result of accu-
mulated mutations in tumor suppressor genes and oncogenes.2 
But the nature of the mutated genes and the order of their 
mutation can vary with different precipitating factors.67,80,81 
Activation of Wnt signaling is seen in the vast majority of 
CRCs.2 Other signaling pathways that are commonly altered 
during CRC progression include activation of K-ras, p53, and 
TGF-β.82 Alterations in the same pathways are frequently seen 
in cases with colitis-associated CRC. In addition, activation 
of NF-κΒ and STAT3 pathways are also detected in colitis-
associated CRC. The sequence and role of these pathway 
alterations in the development of CRC have been reviewed 
previously.59 Here, we will focus on genetic mutations of the 
tumor suppressor APC.
Mutation of APC is by far the most common genetic event 
seen in CRC that leads to Wnt signal activation. Curiously, 
APC mutations are not detected in other Wnt-dependent 
tumors to nearly the same extent as seen in CRC. Rather, in 
non-colonic tumors, mutations in other Wnt components, are 
more commonly found,12 suggesting a colon-specific protec-
tive function of APC that is selected against during CRC 
development. Furthermore, data from AOM–DSS models 
suggest that Wnt signal activation alone is not sufficient for 
effective initiation of colon tumorigenesis. Injection of mice 
with a single dose of AOM, expected to induce oncogenic 
β-catenin mutations which activate Wnt signaling, results 
in no tumors or only a very low incidence of tumors.61,68 
However, combing AOM with DSS-induced inflammation 
results in robust tumor formation. Moreover, patients and 
mice with germ line APC/Apc mutations develop intestinal 
tumors with 100% penetrance.5,9
The data supporting an association between APC muta-
tions and inflammation are overwhelming. Inflammation can 
greatly increase intestinal tumorigenesis in rodent models 
with germ line Apc mutations. DSS treatment of ApcMin/+ 
mice increases their colon tumor multiplicity by 15–30-fold.83 
Unlike AOM-induced tumors in wild-type mice treated with 
DSS, which show β-catenin stabilizing mutations, colonic 
tumors in DSS-treated ApcMin/+ mice typically show loss of 
the wild-type Apc allele.83 The latter mechanism is similar 
to that seen in tumors from ApcMin/+ mice not treated with 
DSS.84 Of note, the multiplicity of tumors in DSS-treated 
ApcMin/+ mice is higher than in wild-type mice treated with 
the mutagen AOM followed by DSS.83 Collectively, these data 
strongly support a colon-specific tumor suppressor function 
for APC beyond that as a Wnt signal antagonist, potentially 
to control colitis.
Experimental induction of inflammation in mouse intesti-
nal tumor models by methods other than DSS administration 
also increases tumorigenesis. Germ line deletion of Il-10 (an 
anti-inflammatory cytokines) or single immunoglobulin Il-1 
receptor-related (SIGIRR) molecule increases intestinal 
tumors in ApcMin/+ mice.85,86 Transgenic expression of Il-8 
(a proinflammatory cytokine) enhances tumorigenesis in 
both AOM–DSS and ApcMin/+ models.87 In addition, Nrf2 
knockout mice display increased oxidative stress, increased 
inflammatory markers, and colitis and accelerated intestinal 
tumorigenesis.88,89 Conversely, reducing inflammation protects 
from intestinal tumorigenesis. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) reduce polyp formation in FAP patients as 
well as in ApcMin/+, Apc∆474/+, and Apc1309/+ mouse models.90–94 
Experimental genetic deletion of proinflammatory mediators 
CXCR2, CD24, TNF-α, and epimorphin significantly reduces 
intestinal tumor numbers in ApcMin/+ mice.95–98
Inflammation might also contribute to some other known 
risk and protective factors in CRC. For example, high fat 
diets and obesity predispose humans to CRC, ApcMin/+ mice 
to increased intestinal polyposis, and AOM-treated mice to 
pre-cancerous colon lesions.99,100 Obesity has been associated 





with adipose tissue macrophage malfunction and low-level 
inflammation.101–103 A recent report showed increased inflam-
matory mediators in ApcMin/+ mice on high fat diet relative to 
ApcMin/+ mice on regular lab diet.104 In addition, many natural 
products including curcumin, grape antioxidant fibers, and 
brown rice reduce colon tumors in various mouse models, 
presumably by reducing inflammation.105–109
The mechanisms by which inflammation can enhance colon 
tumorigenesis are not completely delineated. Inflammation 
activates many pathways that synergize with Wnt signal 
activation in CRC tumorigenesis including AKT, KRAS, 
BRAF, HIF1-α, and TGF-β. DNA damage and epigenetic 
changes that are associated with inflammation could also 
contribute to tumor formation.59
Many inflammatory pathways converge to activate the 
prosurvival NF-κB pathway,59 which is also activated in 
colonic mucosa from IBD patients.110 NF-κB pathway activa-
tion increases proliferation and decreases apoptosis in CRC 
cell lines and mouse colon mucosa,110,111 drugs that inhibit the 
NF-κB pathway decrease intestinal tumorigenesis in ApcMin/+ 
mice.112 Aspirin, an NSAID that decreases intestinal poly-
posis in both mouse models and FAP patients and protects 
from CRC, inhibits the NF-κB pathway and also increases 
Apc/APC expression.113
Inflammation can increase DNA damage and acceler-
ate mutagenesis. The rate of reactive oxygen species (ROS) 
production, including nitric oxide (NO), is augmented in 
inflamed tissues. ROS are genotoxic and increase DNA muta-
tion rates.55,58,114,115 Inhibiting NO production reduces intestinal 
polyp formation in ApcMin/+ mice as well as inflammatory mod-
els of colitis.116,117 Notably, activation of the NF-κB pathway 
by constitutive activation of its upstream activator, IKKβ, 
enhances intestinal polyposis and elevates DNA damage in 
Apc580D/+ mice.118 NO synthase inhibitors reduce this DNA dam-
age and intestinal tumorigenesis, suggesting that accelerating 
Apc LOH (loss of heterozygosity) due to the DNA damaging 
effect of NO is the cause of enhanced tumorigenicity in these 
mice.118 Inflammation may also induce DNA damage by 
increasing the production of other mutagenic factors including 
trans-4-hydroxy-2-nonenal from the activated inflammatory 
cells, which can further induce chromosomal breakage in 
nearby epithelial cells.119 Moreover, chronic inflammation can 
also reduce DNA mismatch repair proteins.120,121
Chronic inflammation is also associated with epigenetic 
changes including changes in miRNA, DNA hypermethyla-
tion, and aberrant methyl histone markings.122 Colitis leads 
to upregulation of miRNA-155123; miRNA-155 targets APC 
and thus, activates β-catenin.124 The protumorigenic effect of 
chronic colitis has also been linked to prostaglandin (PG) for-
mation through induction of cyclooxygenase-2 (COX-2).125 
COX-2 is the rate-limiting step in PGE2 formation from 
arachidonic acid.122 Both Cox-2 and PGE2 promote Wnt 
signaling, increase cellular proliferation, inhibit apopto-
sis, promote angiogenesis, and enhance metastasis.126–129 
Conditional deletion of Cox-2 results in significant reduction 
of intestinal tumors in ApcMin/+ and Apc∆716/+ mice,130,131 Cox-2 
is also targeted by NSAIDs and selective Cox-2 inhibitors 
such as Celebrex, both of which reduce intestinal tumori-
genesis in patients and mouse models with germ line APC/
Apc mutations.122
APC mutations and inflammation
In the previous section we presented evidence that inflam-
mation accelerates intestinal tumorigenesis in the presence 
of Apc mutations. However, there is evidence that Apc 
mutations can enhance colitis. Proinflammatory mediators 
Cox-1, Cox-2, MIP-2, OPN, CXCR-2, and Gro-α mRNA 
are upregulated in colonic polyps in ApcMin/+ mice relative 
to epithelial cells from normal mice.132 Of these genes, only 
Cox-2 is a defined Wnt target.133,134 The other mediators have 
not been linked to activated Wnt signaling resulting from Apc 
mutations. In addition, mRNA and serum protein levels of 
proinflammatory cytokines MCP-1, IL-6, IL-1β, and TNF-α 
increase with the progression of intestinal tumorigenesis and 
correlate with tumor size.135 Moreover, a global expression 
analysis showed differential expression of inflammatory 
genes, Lcn2 and N4wbp4, in ApcMin/+ polyps.136 In another 
mouse model (CPC–APC), conditional truncation of Apc 
in the distal part of the small intestine and colon resulted in 
inflammatory cell infiltration and upregulation of Il-17 and 
Il-23 in the developing polyps.137
Recently, we described a mouse model with a germ line 
Apc mutation that compromises the ability of Apc to locate 
to the nucleus.54 These ApcmNLS/mNLS mice only rarely develop 
tumors, and homozygous mutant mice are viable. However, 
the ApcmNLS allele increases tumor formation when combined 
with the ApcMin allele (ApcmNLS/Min mice).54 Notably, ApcmNLS/mNLS 
mice have higher expression of inflammatory mediators 
Cox-2 and MIP-2 and are more susceptible to DSS-induced 
colitis and AOM–DSS-induced colon tumorigenesis.138 Rats 
with germ line Apc mutation resulting in truncation of the 
C-terminal 300 amino acids (KAD rats) do not develop tumors 
but are also more susceptible to DSS-induced inflammation 
and AOM–DSS-induced colon tumorigenesis.139
APC mutation can induce colitis by several mechanisms. 
First, APC mutations can decrease mucus production and 
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therefore reduce the barrier between gut microbes and 
intestinal tissues.137 Apc normally functions in promoting 
cellular differentiation of intestinal lineages including mucus-
producing goblet cells.23,140 ApcmNLS/mNLS mice have reduced 
expression of Hath-1 and fewer goblet cells in their small 
intestines and less Muc-2 mRNA in their colons, relative 
to their wild-type littermates.54,138 Hath-1 is a transcription 
factor that participates in goblet cell differentiation and is 
negatively regulated by Wnt signaling.17,141 Muc-2 is the 
major protective mucin in the colon. Muc-2 knockout mice 
develop colitis and have spontaneous colonic tumors.142,143 
Muc-2 mutation also enhances intestinal tumorigenesis in 
ApcMin/+ mice.143,144 Furthermore, induction of inflamma-
tion in ApcmNLS/mNLS mice using DSS results in significantly 
fewer goblet cells and reduced Muc-2 mRNA, relative to 
DSS-treated wild-type mice.138 Goblet cell differentiation 
requires low Notch signal and treating ApcMin/+ mice with a 
γ-secretase inhibitor, inhibited Notch signaling and increased 
goblet cell differentiation in intestinal tumors.145 A potential 
link between Notch signaling and APC is that APC is in a 
double negative feedback loop with the transcription inhibitor 
Msi-1.146 Msi-1 activates Notch signaling by inhibiting the 
Notch repressor, Numb.147 In cases of Apc mutation, Msi-1 
is upregulated; activating Notch signaling.23,148 However, 
a direct role of Msi-1 in goblet cell differentiation has not 
been examined. Finally, FAP patients and CPC–APC mice 
with conditional truncation of APC/Apc showed reduced 
mucus production of polyps, which displayed Apc LOH.137 
Colonic mucosa in AOM-treated rats as well as FAP patients 
shows foci with depleted mucin.149,150 These mucin-depleted 
foci are correlated with tumor number and have high rates 
of Apc mutations.151 Apc-mutant (PIRC) rats also show 
mucin-depleted foci that increase in number as the rats age.152 
Notably, the NSAID sulindac, reduces the number of polyps 
as well as mucin-depleted foci in PIRC rats.152 Collectively, 
these data suggest that Apc mutations predispose to the pre-
cancerous mucin-depleted foci.
Alteration of Apc can also affect other intestinal epithe-
lial barrier activities. APC loss effects localization of tight 
junction protein ZO-1.153 Loss of APC and upregulated Wnt 
signaling are also associated with increased expression of 
tight junction protein claudin-1 in CRCs.154 Further, inducible 
Apc truncation in CPC–APC mice leads to reduced junctional 
claudin-3, -4, -5, and -7 and decreased levels of JAM-C 
(junctional adhesion molecule-C) mRNA.137 The C-terminus 
of Apc binds to the junctional protein DLG (Figure 1). In 
KAD rats, Dlg5 fails to localize to the junction in endothelial 
cells, resulting in delayed healing after DSS-induced inflam-
mation.155 Finally, APC interacts with cytoskeletal proteins 
including those of microtubules and intermediate filaments, 
which are important in formation and maintenance of tight 
junctions.31,156,157 Apc mutations alter cytoskeletal organiza-
tion in intestinal epithelial cells and affect cell polarity.158 
Whether these changes in epithelial organization enhance 
colitis is not clear.
Apc mutations might also induce inflammation by acti-
vating Wnt signaling. Cox-2 and iNOS are Wnt targets.134,159 
Cox-2 is the rate-limiting enzyme in PGE2 synthesis. PGE2 
is involved in processes that lead to inflammation, including, 
vasodilation, increasing vascular permeability, and chemo-
attraction of inflammatory cells.59
APC, colitis, and microbiome in CRC
The role of intestinal flora in health and disease is getting 
increasing attention of late.160,161 The development of tools 
such as deep sequencing has allowed rapid analysis of dif-
ferent intestinal bacteria. The gastrointestinal tract in general 
and especially the distal portion is home to a large number of 
microorganisms. The relationship between these florae and 
the host is mostly symbiotic.160,161 The host provides a niche 
and nutrients, while intestinal florae provide essential vita-
mins and are crucial for the development of the host immune 
system. Particular intestinal florae also prevent overgrowth 
of pathogenic microorganisms by competing with them for 
limited resources. However, changes in the number, type, or 
the relative abundance of different intestinal microorganisms 
(dysbiosis) have been related to many pathological condi-
tions including IBD and CRC.160,162 The challenging task for 
the intestinal epithelial barrier is to regulate the intestinal 
microbiome by allowing the growth of beneficial species 
and preventing the growth and invasion of pathogenic and 
opportunistic organisms.
Disruption of the intestinal epithelial barrier is a hallmark 
of IBD.163 However, the relationship between the epithelial 
barrier, intestinal florae, and inflammation has multiple levels 
of complexity. Mucus secretion is stimulated by bacterial 
colonization.164 Germ-free mice have a thin mucus layer, 
which can be restored to normal thickness by bacterial prod-
ucts including peptidoglycans and lipopolysaccharides.164,165 
Bacterial products including butyrate and short chain fatty 
acids also can induce Muc2 transcription via c-Fos/c-Jun and 
by epigenetic histone alterations.166–169 On the other hand, 
microbes or their metabolic products may induce inflam-
matory reactions in the colon. Some intestinal florae such as 
Fusobacteria and Surpulina are enriched in the mucus layer 
covering regions of enteric inflammation,170,171 consistent 





with their ability to dissolve the mucus layer and thus provide 
access to other microbes.172 Clostridia-like gram-positive seg-
mented filamentous bacteria induce intestinal inflammation 
which predisposes to colitis but also protects mice from some 
enteric infections.173 In contrast, some bacterial products 
such as short chain fatty acids and butyrate inhibit colitis by 
stimulating epithelial cells to secrete the anti-inflammatory 
cytokines IL-10 and IL-18.174–176
Several mechanisms linking the colonic microbiome to 
CRC have been proposed. In human patients, the florae of 
colonic adenomas and adenocarcinomas are enriched with 
fusobacterial species relative to normal colon tissue.177,178 
Fusobacteria enhance intestinal tumorigenesis in ApcMin/+ 
mice resulting in a proinflammatory gene expression sig-
nature in the tumor cells.177 Reducing microbial-induced 
inflammation by deleting the PAMP pathway adaptor 
protein Myd88 decreases intestinal tumors in ApcMin/+ mice 
and colon tumors in AOM-treated mice.179,180 Furthermore, 
transplantation of bone marrow from mice with mutations 
in genes encoding PAMP adaptor proteins Myd88, Tlr2, 4, 
and 9 reduces inflammation and tumor load in CPC–APC 
mice.137 Finally, deletion of anti-inflammatory cytokine 
Il-10 alters the intestinal microbiota and increases the 
intestinal tumor number in Apc∆468 mice; treating these 
mice with broad-spectrum antibiotics decreased the overall 
microbial diversity and also decreased the intestinal tumor 
multiplicity.181
Microorganisms can also secrete carcinogenic metabo-
lites that can mutate DNA. In addition to ROS produced by 
inflammatory cells as the result of bacterial-induced inflam-
mation, some colonic bacteria including the gram-positive 
Enterococcus faecalis produce hydroxyl radicals.182–184 
Still, other colon-inhabitant gram-negative, Escherichia 
coli, produce a toxin that can cause DNA damage and 
CRC.185 Bacteria may also secrete chemicals that directly 
induce proliferation. For example, the exotoxin fragilysin 
secreted by some Bacteroid species induces c-Myc which 
stimulates cellular proliferation.186 Bacterial metabolites 
such as H
2
S are produced by many Enterobacterial species 
commonly found in the normal colon.187 H
2
S can activate 






















Figure 3 Potential roles for APC in inflammation.
Notes: APC normally promotes differentiation of goblet cells which generate and secrete mucus. Protective mucus layers provide a physical barrier between luminal 
microbes and the epithelial cells lining the intestine. APC interacts with various junctional proteins, further contributing to a barrier between the luminal contents and the 
immune cells of the stroma. APC regulates expression of genes, some of which are involved in inflammation. Microbial breach of the intestinal barrier results in inflammation. 
Consequences of inflammation include DNA damage and epigenetic changes that can result in additional mutation of tumor suppressor genes and oncogenes that further 
promote colorectal carcinogenesis.
Abbreviations: APC, adenomatous polyposis coli; iNOS, induced nitric oxide synthase; CRC, colorectal cancer; ROS, reactive oxygen species; COX-2, cyclooxygenase-2.




Animal models of colon cancer: inflammation control on APC
Several observations made in mouse models point to an 
interaction between genetic lesions, intestinal florae and CRC. 
Smad3-deficient mice develop colon tumors only in the pres-
ence of helicobacter infection.189 Tbx2 and Rag2-/- ulcerative 
colitis (TRUC) mice develop colitis and colitis-associated 
colon cancer, but not when raised in a germ-free environ-
ment.190 Similarly, Il10-/- mice develop colitis-associated 
colon tumors only if they have intestinal bacteria.191 NLRP6 
is a component of the innate immune response that senses 
microbes, and NLRP6 deletion in intestinal epithelial cells 
induces colitis and colitis-associated tumorigenesis.192 These 
NLRP6-deficient mice also have changes in the bacterial flora 
composition with more abundant Bacteroids in the colon. 
Remarkably, cohousing these NLRP6-mutant mice with wild-
type mice results in development of colitis and colon tumors 
in the wild-type mice, consistent with transmissible tumor 
promoter.192,193 A similar transmissible, tumor-promoter has 
been described in mice with mutations in other compo-
nents of the innate immune response, NOD2 and RIP2.194 
Furthermore, expression of the secreted anti-inflammation 
mediator/antimicrobial, Pla2g2a in intestinal epithelial cells 
reduces the incidence of intestinal polyps in ApcMin/+ mice and 
in orthotopic xenografts of human colon cancer cells.195,196 
Notably, exogenous expression of the Pla2g2a gene pre-
vents colon tumorigenesis in Muc2-deficient mice.197
Although connections are starting to emerge, the precise 
relationship between the tumor suppressor Apc and intestinal 
flora is not well defined. ApcMin/+ mice raised in a germ-free 
environment develop fewer polyps than ApcMin/+ mice housed 
in standard conditions.198 However, this tumor reduction is 
statistically significant only in the middle portion of the small 
intestine, with no reduction in the number of tumors in the 
colon.198 This region specificity may represent a varied role 
for different microbial species in discrete regions of the gas-
trointestinal tract. On the other hand, Apc∆14/+ mice developed 
more polyps when raised in germ-free conditions than in 
standard housing conditions.199 Together, these data suggest 
an allele-specific interaction of Apc with the microbial con-
tent of the gut. Notably, mutations in ApcMin/+ and Apc∆14/+ are 
expected to result in truncated Apc proteins that differ by 403 
amino acids.5 The contrasting effect of germ-free conditions 
on polyp number in ApcMin/+ and Apc∆14/+could also represent 
other contributing factors that vary between the two experi-
mental conditions including other genetic loci and diet.4
Conclusion
The results gathered from studies of rodent CRC models 
reveal a complex interplay of genetics, inflammation, and 
the microbiome that gives rise to a cancer phenotype. APC 
is a major tumor suppressor in the colon. Although the 
most universally appreciated APC role is that of Wnt signal 
antagonist, APC is multifaceted. In this review, we describe 
an emerging role for APC in colitis. We propose that this 
APC role as regulator of the inflammatory response might 
be particularly critical in the colon and thus contribute to the 
high frequency of APC mutations seen in CRC compared to 
cancers of other tissues (Figure 3). Unearthing the precise 
role for APC in suppression of inflammation will expand 
the repertoire of therapeutic strategies aimed at rescuing the 
functions of this multifaceted and fascinating tumor sup-
pressor protein.
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